Cytisinicline: The New Quit Vaping Drug Awaiting FDA Approval in 2026

For the first time in nearly two decades, the United States is on the verge of getting a brand-new prescription drug for nicotine dependence. Cytisinicline, developed by Achieve Life Sciences, has a Prescription Drug User Fee Act (PDUFA) target date of June 20, 2026 for smoking cessation, and the FDA has already granted it both a Breakthrough Therapy Designation and a Commissioner’s National Priority Voucher for the e-cigarette and vaping cessation indication. If approved on schedule, it would be the first prescription medication ever specifically targeted at vaping cessation. Here’s what the data shows, how it stacks up against existing options, and whether it’s likely to be worth the wait.

What cytisinicline actually is

Cytisinicline is a purified, pharmaceutical version of cytisine, a naturally occurring alkaloid found in the seeds of the Laburnum tree (also called the golden chain tree). Cytisine has been used as a smoking cessation aid in Central and Eastern Europe since the 1960s under brand names like Tabex, but its dosing was never optimized for modern clinical practice. Cytisinicline is the same molecule, refined to a higher purity and supported by Phase 3 trials that meet U.S. regulatory standards.

The mechanism is similar to varenicline (Chantix): it binds to the alpha-4 beta-2 nicotinic acetylcholine receptor — the same receptor nicotine binds to. But unlike nicotine, which fully activates the receptor and floods the brain with dopamine, cytisinicline only partially activates it. The result is a moderate dopamine release that takes the edge off cravings, while simultaneously blocking nicotine itself from binding effectively. If you vape or smoke while taking cytisinicline, the nicotine hit is significantly less rewarding.

If you’ve explored prescription quit drugs before, this mechanism will sound familiar — it’s essentially the same playbook as Chantix. The differences are in safety profile, dosing duration, and approval indication.

The clinical evidence so far

Two published Phase 3 trials and one ongoing safety study form the basis of the New Drug Application currently with the FDA.

ORCA-2 (smoking cessation) randomized 810 adult smokers to 6 weeks of cytisinicline, 12 weeks of cytisinicline, or placebo. Results published in JAMA in 2023: continuous abstinence rates at week 24 were 32.6% in the 12-week cytisinicline arm versus 7.0% in placebo — roughly a 4.6-fold improvement. Side effects were mild: insomnia, abnormal dreams, and mild nausea were the most common (Rigotti et al., JAMA, 2023).

ORCA-3 (smoking cessation) repeated those findings in a separate cohort of 792 smokers, with similar abstinence rates and a similarly favorable safety profile.

ORCA-V1 (vaping cessation) is the trial that gets the most attention from clinicians focused on younger patients. Published in JAMA Internal Medicine in 2024, it randomized 160 adult vapers to either 12 weeks of cytisinicline plus behavioral support, or placebo plus behavioral support. Continuous abstinence at the end of treatment was 31.8% with cytisinicline versus 15.1% with placebo — meaning cytisinicline-treated participants were about 2.6 times more likely to quit vaping (JAMA Internal Medicine, 2024).

For context, that’s a significantly better effect size than nicotine patches alone (which roughly double quit rates) and competitive with the best combination NRT protocols.

How cytisinicline compares to Chantix (varenicline)

This is the comparison most current Chantix users want answered. Both drugs target the same receptor, both are partial agonists, and both have demonstrated meaningfully better efficacy than NRT alone. The differences:

Efficacy: Head-to-head trials are limited, but a 2023 indirect meta-analysis suggested varenicline still has a slight edge in pure abstinence rates at 6 months — roughly 3.0x vs. 2.6x odds ratio over placebo. The gap is small and may close with optimized cytisinicline dosing.

Side effect profile: Varenicline carries a long history of psychiatric side-effect concerns, including the FDA’s now-removed black box warning about depression and suicidal ideation. The warning was lifted in 2016 after the EAGLES trial showed no significant increase in psychiatric events, but the perception remains. Cytisinicline trials so far have shown a notably cleaner psychiatric safety profile, with no serious mental health adverse events attributed to the drug.

Treatment duration: Standard varenicline treatment is 12 weeks, often extended to 24. Cytisinicline trials have shown comparable results at 6 to 12 weeks, potentially shortening the treatment course and improving adherence.

Cost (projected): Varenicline went generic in 2021, and generic varenicline typically costs $100-$200 for a 12-week course with insurance, or $300-$600 cash. Cytisinicline pricing is unknown until launch, but Achieve Life Sciences has signaled commercial pricing in line with branded prescription cessation drugs at launch. Generics are years away.

Approval indication: This is the key differentiator. Varenicline is approved for smoking cessation only — vaping cessation is off-label. Cytisinicline is being pursued explicitly for both smoking AND vaping cessation, with the vaping indication receiving the FDA’s accelerated review pathway. If approved as labeled, it would be the first prescription drug specifically authorized for quitting vaping in the U.S.

For more context on how Chantix compares to other options today, see our Chantix alternatives guide.

Why the vaping indication matters

Roughly 11 million U.S. adults vape, and an estimated 8.1 million are dependent enough to meet diagnostic criteria for nicotine use disorder (CDC, 2024). Until now, every cessation tool — patches, gum, lozenges, varenicline, bupropion — has been studied primarily in smokers. Vapers have been forced to extrapolate from smoking data, and the extrapolation isn’t perfect: vape devices deliver nicotine more efficiently and more frequently than cigarettes, and modern nicotine salt formulations create a different dependence profile.

A drug studied and approved specifically for vaping cessation matters because:

1. Insurance coverage will follow the indication. Once cytisinicline is approved for vaping, insurance plans will be required to cover it for that diagnosis. Currently, varenicline coverage for vaping is hit-or-miss because of its smoking-only label.
2. Clinicians will prescribe more confidently. Many primary care physicians decline to prescribe varenicline off-label for vapers; an on-label option removes that hesitation.
3. The data informs dosing. ORCA-V1 used a vaping-specific dosing protocol, providing the first evidence-based dosing guidance for vapers rather than back-calculating from smoking trials.

For most current vapers exploring the best way to quit nicotine, this means a meaningfully expanded toolkit by late 2026.

The expected timeline

Based on Achieve Life Sciences’ public communications and the FDA’s stated review schedule:

• June 20, 2026 (PDUFA date for smoking indication): The FDA must issue a decision — approval, complete response letter, or extension — by this date for the smoking cessation indication.
• Late Q3 to Q4 2026: If approved, Achieve plans U.S. commercial launch by end of year, initially through specialty pharmacies and direct-to-prescriber channels.
• 2027 (vaping indication): The vaping cessation New Drug Application is expected to be filed after smoking-indication approval, leveraging the FDA Commissioner’s Priority Voucher to accelerate review. Realistic vaping-indication approval is likely mid- to late-2027.
• Generic availability: No earlier than 2030, given typical patent and exclusivity timelines for new chemical entities.

What to do in the meantime

Don’t wait. Roughly 70 to 80% of people who try to quit nicotine relapse within the first week (CDC, 2024), and the longer you postpone the attempt, the more dependence accumulates. Existing tools work — they’re just less effective than what’s coming.

If you’re a vaper deciding whether to quit now or wait for cytisinicline:

• If you have a clear quit window now (job change, life event, supportive partner) — start now with combination NRT or, if appropriate, off-label varenicline. The success rate at 6 months is 25-35% with combination NRT plus behavioral support — high enough that waiting another 12-18 months for a marginally better drug rarely justifies the delay.
• If you’ve already tried twice and failed on NRT alone — talk to your clinician about generic varenicline now, with the option to switch to cytisinicline at launch if needed.
• If you’re a heavy multi-pod-per-day vaper with severe dependence — cytisinicline’s vaping-specific data is genuinely promising. It may be worth a short delay to access the labeled product, but make sure you have a structured taper or partial-NRT bridge plan in the meantime.

The bottom line

Cytisinicline isn’t a magic bullet, but it’s the most meaningful new prescription cessation option in nearly twenty years, and the first one designed and tested specifically with vapers in mind. Approval for the smoking indication looks likely by June 2026, with vaping approval probably following in 2027. Roughly 32% continuous abstinence at end of treatment in the ORCA-V1 vaping trial — vs. 15% for placebo — represents a meaningful real-world improvement over what’s currently available off-label.

If you’ve been delaying a serious quit attempt, the right move is still to start now with the proven tools available today. But for the millions of vapers who’ve tried and failed, or who aren’t great candidates for current NRT options, cytisinicline is genuinely worth tracking. We’ll update this guide the moment the FDA decision lands.

When will cytisinicline be FDA approved?

The PDUFA target date for the smoking cessation indication is June 20, 2026. If approved, U.S. commercial launch is expected by late 2026. The separate vaping cessation indication is expected to follow in 2027 after a separate New Drug Application using the FDA Commissioner’s Priority Voucher.

Is cytisinicline better than Chantix?

The evidence so far suggests roughly comparable efficacy — Chantix may have a slight edge at 6-month abstinence, while cytisinicline has shown a cleaner psychiatric side-effect profile in trials and would be the first prescription drug labeled specifically for vaping cessation. Most clinicians will likely consider both options based on patient history and tolerance.

Will cytisinicline work for quitting vaping?

The ORCA-V1 trial showed 31.8% continuous abstinence at end of treatment in vapers using cytisinicline plus behavioral support, compared to 15.1% on placebo — about 2.6 times more likely to quit. This is meaningfully better than nicotine patches alone for vaping cessation.

How much will cytisinicline cost?

Pricing has not been announced. Achieve Life Sciences has signaled commercial pricing in line with branded prescription cessation drugs at launch. Expect insurance coverage similar to varenicline once approved, with cash pricing likely in the $400-$700 range for a full course before generics arrive in approximately 2030.

Can I get cytisinicline now?

Cytisinicline is not yet FDA approved and is not legally available in the U.S. outside of clinical trials. The closely related original cytisine is sold in Eastern European countries and online, but importing prescription drugs without FDA approval carries legal and quality risks. The recommended path is to use existing approved options like combination NRT or generic varenicline now, then switch to cytisinicline after approval if appropriate.